The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?

被引：35
作者：
Giordano T.P. [1 ]
Suarez-Almazor M.E. [1 ]
Grimes R.M. [1 ]
机构：
[1] Houston Center for Quality of Care and Utilization Studies, Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard (VA152), Houston, 77030, TX
来源：
Current HIV/AIDS Reports | 2005年 / 2卷 / 4期
基金：
美国国家卫生研究院;
关键词：
Human Immunodeficiency Virus; Human Immunodeficiency Virus Infection; Human Immunodeficiency Virus Testing; Undetectable Viral Load; Human Immunodeficiency Virus Care;
D O I：
10.1007/s11904-005-0013-7
中图分类号：
学科分类号：
摘要：
Despite the success of highly active antiretroviral therapy (HAART) at reducing mortality from HIV infection, there is evidence that it is not reaching the all of the population that needs it, even in the developed world. To be maximally effective at the population level, all persons with HIV infection must be diagnosed; those persons with an indication for HAART must enter care, must receive HAART, and then must adhere to appointments and, finally, HAART itself. There is considerable evidence that significant portions of the population infected with HIV have not completed all of these steps of HIV care even in the developed world. Although new medications to treat HIV are certainly needed, significant improvements in viral, immunologic, and clinical outcomes could be achieved from improving timely diagnosis, access to HAART, and adherence to appointments, as well as adherence to HAART.
引用
收藏
页码：177 / 183
页数：6
相关论文
共 135 条
  • [1] Wood E(2003)Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world AIDS 17 2419-2427
  • [2] Montaner JS(2000)Distinguishing efficacy, individual effectiveness and population effectiveness of therapies AIDS 14 754-756
  • [3] Bangsberg DR(2001)The serostatus approach to fighting the HIV epidemic: Prevention strategies for infected individuals Am J Public Health 91 1019-1024
  • [4] Munoz A(2004)Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy J Infect Dis 190 285-292
  • [5] Gange SJ(2003)Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999–2000 Clin Infect Dis 36 1030-1038
  • [6] Jacobson LP(2002)Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies Lancet 360 119-129
  • [7] Janssen RS(2002)Trends in AIDS incidence and survival among racial/ethnic minority men who have sex with men, United States, 1990–1999 J Acquir Immune Defic Syndr 31 339-347
  • [8] Holtgrave DR(2003)Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data Am J Public Health 93 1728-1733
  • [9] Valdiserri RO(2002)Potential barriers to seeking human immunodeficiency virus testing among adults in the United States: data from the 1998 National Health Interview Survey AIDS Patient Care STDS 16 293-299
  • [10] Recsky MA(2004)Following-up for HIV test results: what limits return in an STD clinic population Int J STD AIDS 15 29-32
12345678910